First effective immunotherapy against bladder cancer
The team comes from centers in France, the U.S. and Spain. (Photo Archive)

An international team of researchers presented the first Saturday of next generation immune therapy can shrink tumors in bladder cancer. 43 percent of patients who participated in the work viewed reduced the size of their tumors, the researchers said.
It is a targeted therapy and progress in immunotherapy, treatment of disease by enhancing or weakening of the immune mechanisms.
Specifically, researchers, centers of the U.S., France and Spain, used a drug-in-a monoclonal antibody research designed to block a protein called PD-L1.
From a total of 68 patients were selected for this study 30, which had previously received standard therapy and whose tumors had been characterized as positive for PD-L1 (which have altered the protein).
The tumor cells are able to evade the immune system and make it in multiple ways. Each type of impairment that makes the tumor cell to the immune system is called checkpoint.
“It’s the first time”, according to this expert, “one of these new-generation immunotherapies is investigated in bladder cancer” and “is particularly surprising that the treatment efficiency achieved.” Metastatic bladder carcinoma is associated with poor prognosis and limited therapeutic options. It is the ninth most common cancer worldwide.